Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Risk factors for fluconazole-resistant Candida glabrata bloodstream infections.

Lee I, Fishman NO, Zaoutis TE, Morales KH, Weiner MG, Synnestvedt M, Nachamkin I, Lautenbach E.

Arch Intern Med. 2009 Feb 23;169(4):379-83. doi: 10.1001/archinte.169.4.379.

2.

Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.

Tumbarello M, Sanguinetti M, Trecarichi EM, La Sorda M, Rossi M, de Carolis E, de Gaetano Donati K, Fadda G, Cauda R, Posteraro B.

J Antimicrob Chemother. 2008 Dec;62(6):1379-85. doi: 10.1093/jac/dkn381. Epub 2008 Sep 8.

PMID:
18782778
3.

Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection: potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance.

Lee I, Zaoutis TE, Fishman NO, Morales KH, Nachamkin I, Lautenbach E.

Am J Infect Control. 2010 Aug;38(6):456-60. doi: 10.1016/j.ajic.2009.12.011. Epub 2010 Apr 3.

PMID:
20371135
4.

Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections.

Lee I, Morales KH, Zaoutis TE, Fishman NO, Nachamkin I, Lautenbach E.

Am J Infect Control. 2010 Nov;38(9):740-5. doi: 10.1016/j.ajic.2010.02.016. Epub 2010 Jun 12.

5.

Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.

Klevay MJ, Horn DL, Neofytos D, Pfaller MA, Diekema DJ; PATH Alliance.

Diagn Microbiol Infect Dis. 2009 Jun;64(2):152-7. doi: 10.1016/j.diagmicrobio.2009.03.007. Epub 2009 Apr 18.

PMID:
19376667
6.

Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.

Ruan SY, Huang YT, Chu CC, Yu CJ, Hsueh PR.

Int J Antimicrob Agents. 2009 Sep;34(3):236-9. doi: 10.1016/j.ijantimicag.2009.02.021. Epub 2009 Apr 9.

PMID:
19361960
7.

Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients.

Cohen Y, Karoubi P, Adrie C, Gauzit R, Marsepoil T, Zarka D, Clec'h C.

Crit Care Med. 2010 Mar;38(3):826-30. doi: 10.1097/CCM.0b013e3181cc4734.

PMID:
20042858
8.

Candida and candidaemia. Susceptibility and epidemiology.

Arendrup MC.

Dan Med J. 2013 Nov;60(11):B4698. Review.

PMID:
24192246
9.

Risk factors for fluconazole-resistant candidemia.

Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Aznar-Martín J, Cisneros JM, Ortiz-Leyba C.

Antimicrob Agents Chemother. 2010 Aug;54(8):3149-54. doi: 10.1128/AAC.00479-10. Epub 2010 May 24.

10.

Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.

Ben-Ami R, Olshtain-Pops K, Krieger M, Oren I, Bishara J, Dan M, Wiener-Well Y, Weinberger M, Zimhony O, Chowers M, Weber G, Potasman I, Chazan B, Kassis I, Shalit I, Block C, Keller N, Kontoyiannis DP, Giladi M; Israeli Candidemia Study Group.

Antimicrob Agents Chemother. 2012 May;56(5):2518-23. doi: 10.1128/AAC.05947-11. Epub 2012 Feb 6.

11.

Prior antimicrobial exposure and the risk for bloodstream infection with fluconazole-non-susceptible Candida strains.

Hebert C, Villaran R, Tolentino J, Best L, Boonlayangoor S, Pitrak D, Lin M, Weber SG.

Scand J Infect Dis. 2010 Jul;42(6-7):506-9. doi: 10.3109/00365541003699631.

PMID:
20370357
12.

Fluconazole use as an important risk factor in the emergence of fluconazole-resistant Candida glabrata fungemia.

Tumbarello M, Posteraro B, Trecarichi EM, Sanguinetti M.

Arch Intern Med. 2009 Aug 10;169(15):1444-5; author reply 1445. doi: 10.1001/archinternmed.2009.243. No abstract available.

PMID:
19667313
13.

Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit.

Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, Chawla V, Young J, Hadley S.

Clin Infect Dis. 2008 Apr 15;46(8):1206-13. doi: 10.1086/529435.

PMID:
18444857
14.

A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia.

Wilson AG, Micek ST, Ritchie DJ.

Clin Ther. 2005 Aug;27(8):1228-37.

PMID:
16199247
15.

Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.

Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramoju P, Weber SG.

Antimicrob Agents Chemother. 2005 Nov;49(11):4555-60.

16.

Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.

Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA.

J Clin Microbiol. 2006 May;44(5):1740-3.

17.
18.

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ.

J Clin Microbiol. 2003 May;41(5):2176-9.

19.

Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.

Shorr AF, Lazarus DR, Sherner JH, Jackson WL, Morrel M, Fraser VJ, Kollef MH.

Crit Care Med. 2007 Apr;35(4):1077-83.

PMID:
17312565
20.

Candida glabrata fungemia: experience in a tertiary care center.

Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA.

Clin Infect Dis. 2005 Oct 1;41(7):975-81. Epub 2005 Aug 24.

PMID:
16142662

Supplemental Content

Support Center